Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification.
Ann Oncol
; 24(10): 2594-2600, 2013 Oct.
Article
en En
| MEDLINE
| ID: mdl-23899839
ABSTRACT
BACKGROUND:
Even if detected at an early stage, a substantial number of lung cancers relapse after curative surgery. However, no method for distinguishing such tumors has yet been established. PATIENTS ANDMETHODS:
The copy number of the actinin-4 (ACTN4) gene was determined by fluorescence in situ hybridization on tissue microarrays comprising 543 surgically resected adenocarcinomas of the lung.RESULTS:
Amplification (an increase in the copy number by ≥ 2.0 fold) of the ACTN4 gene was detected in two of seven lung adenocarcinoma cell lines and 79 (15%) of 543 cases of pathological stage I-IV lung adenocarcinoma. Multivariate analysis revealed that ACTN4 gene amplification was the most significant independent factor associated with an extremely high risk of death (hazard ratio, 6.78; P = 9.48 × 10(-5), Cox regression analysis) among 290 patients with stage I lung adenocarcinoma. The prognostic significance of ACTN gene amplification was further validated in three independent cohorts totaling 1033 patients.CONCLUSIONS:
Amplification of the ACTN4 gene defines a small but substantial subset of patients with stage I lung adenocarcinoma showing a distinct outcome. Such patients require intensive medical attention and might benefit from postoperative adjuvant chemotherapy.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Actinina
/
Adenocarcinoma
/
Carcinoma de Pulmón de Células no Pequeñas
/
Dosificación de Gen
/
Variaciones en el Número de Copia de ADN
/
Neoplasias Pulmonares
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Ann Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2013
Tipo del documento:
Article